Literature DB >> 9716190

Proliferative vitreoretinopathy: an overview.

J C Pastor1.   

Abstract

Proliferative vitreoretinopathy (PVR) is still the most common cause of failure of surgery for rhegmatogenous retinal detachment, despite the substantial effort that has been devoted to better understanding and managing this condition during the past 25 years. Basic research has indicated that PVR represents scarring, the end stage of the wound-healing process that occurs after retinal detachment surgery. Medical treatment has been directed toward preventing inflammation, the first phase of the wound healing process, and inhibiting cell proliferation, the second phase. The 1983 Retina Society classification was modified in 1989 by the Silicone Study Group, whose classification differentiates between posterior and anterior forms of PVR and recognizes three patterns of proliferation: diffuse, focal, and subretinal. The anterior form has a worse prognosis than the posterior form, and its treatment requires more complex surgical procedures. In this review, risk factors and pathobiology of PVR are discussed, and management of PVR of various degrees of severity are considered.

Entities:  

Mesh:

Year:  1998        PMID: 9716190     DOI: 10.1016/s0039-6257(98)00023-x

Source DB:  PubMed          Journal:  Surv Ophthalmol        ISSN: 0039-6257            Impact factor:   6.048


  105 in total

1.  Intravitreal invading cells contribute to vitreal cytokine milieu in proliferative vitreoretinopathy.

Authors:  I A El-Ghrably; H S Dua; G M Orr; D Fischer; P J Tighe
Journal:  Br J Ophthalmol       Date:  2001-04       Impact factor: 4.638

2.  Nonsteroid anti-inflammatory therapy suppresses the development of proliferative vitreoretinopathy more effectively than a steroid one.

Authors:  Marina V Tikhonovich; Aleksei K Erdiakov; Svetlana A Gavrilova
Journal:  Int Ophthalmol       Date:  2017-06-21       Impact factor: 2.031

3.  Evaluation of supporting role of a foldable capsular vitreous body with magnetic resonance imaging in the treatment of severe retinal detachment in human eyes.

Authors:  R Zhang; T Wang; C Xie; X Lin; Z Jiang; Z Wang; Y Liu; Y Luo; C Long; L He; P Wang; Q Gao
Journal:  Eye (Lond)       Date:  2011-03-18       Impact factor: 3.775

4.  Indocyanine green-assisted peeling of the epiretinal membrane in proliferative vitreoretinopathy.

Authors:  Hidehisa Sakamoto; Ichiro Yamanaka; Toshiaki Kubota; Tatsuro Ishibashi
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2003-02-20       Impact factor: 3.117

5.  Oxidized porous silicon particles covalently grafted with daunorubicin as a sustained intraocular drug delivery system.

Authors:  Jay Chhablani; Alejandra Nieto; Huiyuan Hou; Elizabeth C Wu; William R Freeman; Michael J Sailor; Lingyun Cheng
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-02-01       Impact factor: 4.799

6.  Retinal MMP-12, MMP-13, TIMP-1, and TIMP-2 expression in murine experimental retinal detachment.

Authors:  Bongsu Kim; Mohamed H Abdel-Rahman; Tiffany Wang; Severin Pouly; Ashraf M Mahmoud; Colleen M Cebulla
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-04-03       Impact factor: 4.799

7.  Chemokine CXCL-1: activity in the vitreous during proliferative vitreoretinopathy.

Authors:  C Symeonidis; S Androudi; I Georgalas; A Tzamalis; N Chalvatzis; T Rotsos; E Souliou; E Diza; S A Dimitrakos
Journal:  Clin Exp Immunol       Date:  2015-08       Impact factor: 4.330

8.  Intrasilicone oil injection of bevacizumab at the end of retinal reattachment surgery for severe proliferative vitreoretinopathy.

Authors:  K Ghasemi Falavarjani; M Hashemi; M Modarres; A Hadavand Khani
Journal:  Eye (Lond)       Date:  2014-02-21       Impact factor: 3.775

Review 9.  Recent perspectives on the delivery of biologics to back of the eye.

Authors:  Mary Joseph; Hoang M Trinh; Kishore Cholkar; Dhananjay Pal; Ashim K Mitra
Journal:  Expert Opin Drug Deliv       Date:  2016-09-06       Impact factor: 6.648

10.  Ranibizumab is a potential prophylaxis for proliferative vitreoretinopathy, a nonangiogenic blinding disease.

Authors:  Steven Pennock; David Kim; Shizuo Mukai; Matthew Kuhnle; Dal W Chun; Joanne Matsubara; Jing Cui; Patrick Ma; David Maberley; Arif Samad; Robert J Van Geest; Sarit L Oberstein; Reinier O Schlingemann; Andrius Kazlauskas
Journal:  Am J Pathol       Date:  2013-04-09       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.